ALLMedicine™ Alanine Aminotransferase Center
Research & Reviews 3,829 results
https://doi.org/10.2217/pgs-2021-0064
Pharmacogenomics Sundbaum JK, Baecklund E et. al.
Sep 16th, 2021 - Aim: To identify novel genetic variants predisposing to elevation of Alanine aminotransferase (ALT) in rheumatoid arthritis (RA) patients after initiation of methotrexate (MTX) treatment. Patients & methods: We performed genome-wide association st...
https://doi.org/10.1007/s40520-021-01979-9 10.1503/cmaj.1040752 10.7326/0003-4819-137-1-200207020-00006 10.7326/0003-4819-137-1-200207020-00012 10.1111/j.1423-0410.1988.tb05083.x 10.1002/hep.510270505 10.1053/j.gastro.2019.11.312 10.1016/j.dld.2014.05.021 10.1111/j.1572-0241.2005.41822.x 10.1016/0925-4439(95)00024-X 10.1016/S0891-5849(98)00025-2 10.1002/hep.510240536 10.1111/j.1365-2036.2012.05224.x 10.1136/bmj.38050.593634.63 10.1002/hep.22109 10.1007/s004200050299 10.1053/j.gastro.2008.10.052 10.1136/jech.39.4.337 10.1016/j.ejim.2014.10.019 10.14309/ajg.0000000000000332 10.1111/j.1532-5415.2000.tb03873.x 10.1016/j.jhep.2018.03.018 10.1093/gerona/56.3.M146 10.1093/geront/10.1_Part_1.20 10.1093/ageing/afy169 10.1080/02701367.1999.10608028 10.1111/j.1532-5415.2008.02126.x 10.1016/0022-3956(75)90026-6 10.1046/j.1532-5415.2003.51534.x 10.1002/hep.21171 10.1016/j.atherosclerosis.2008.12.012 10.1093/gerona/glq082 10.1111/j.1532-5415.2006.00921.x 10.1093/gerona/glx126 10.1111/liv.12311 10.18632/oncotarget.9821 10.1002/hep.23200
Aging Clinical and Experimental Research; Gallo P, De Vincentis A et. al.
Sep 11th, 2021 - Recent studies identified low levels of alanine aminotransferase (ALT) as strong predictors of mortality in older people. Here we verified if the combined evaluation of aminotransferases may improve risk stratification for adverse outcomes in olde...
https://doi.org/10.1111/1756-185X.14217
International Journal of Rheumatic Diseases; Wang ST, Tseng CW et. al.
Sep 11th, 2021 - The aim of this study was to investigate hepatitis B virus (HBV) reactivation in patients with rheumatoid arthritis (RA) receiving tofacitinib. This was a retrospective study performed in a regional teaching hospital in southern Taiwan. During Jan...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419385
Digestive Diseases and Sciences; Sobotka LA, Esteban J et. al.
Sep 7th, 2021 - The prevalence and significance of acute liver injury in patients with COVID-19 are poorly characterized. Patients with confirmed COVID-19 who were hospitalized in geographically diverse medical centers in North America were included. Demographics...
https://doi.org/10.1111/ijcp.14775
International Journal of Clinical Practice; Rathore SS, Manju AH et. al.
Sep 5th, 2021 - Crimean-Congo haemorrhagic fever (CCHF) is a fatal acute tick-borne viral infection and substantial emerging global public health threat. This illness has a high case fatality rate of up to 40%. The liver is one of the important target organs of t...
Guidelines 2 results
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.
Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...
https://doi.org/10.1002/hep.23934
Hepatology (Baltimore, Md.); Jonas MM, Block JM et. al.
Oct 5th, 2010 - Chronic hepatitis B virus (HBV) infection in children presents a therapeutic challenge for the practitioner. Decisions regarding selection of patients who may benefit from treatment, appropriate timing of treatment, and the choice of antiviral the...
Drugs 37 results see all →
Clinicaltrials.gov 4 results
https://clinicaltrials.gov/ct2/show/NCT01320943
Aug 29th, 2017 - The primary objective of this study is to evaluate hepatitis B surface antigen (HBsAg) loss and seroconversion in participants who stop tenofovir disoproxil fumarate (TDF) (Stop TDF arm) compared to participants who continue TDF (Continue TDF arm)...
https://clinicaltrials.gov/ct2/show/NCT01325805
Nov 25th, 2016 - The purpose of this study is to investigate the impact of a structured weight loss program versus traditional weight-loss counseling on pregnancy outcomes in women with recurrent pregnancy loss. The study protocol is as follows: Patients will be n...
https://clinicaltrials.gov/ct2/show/NCT01329562
Apr 9th, 2014 - This double-blind multi-site study will be conducted to enroll 40 evaluable participants. All subjects will be medically stable at enrollment and be on a stabilized dosage of daily medications. At Visit 1 (Baseline) following Informed Consent, a p...
https://clinicaltrials.gov/ct2/show/NCT01337791
Apr 19th, 2011 - Telbivudine reduces DNA and normalizes alanine aminotransferase levels (ALT) in chronic hepatitis B patients with few adverse effects, but its use during pregnancy has not been explored. In this open-label, prospective study from the second trimes...
News 229 results
https://www.onclive.com/view/adverse-events-in-her2-positive-metastatic-breast-cancer-treatment
Jul 15th, 2021 - Sara A. Hurvitz, MD: Longer-term safety data were also presented at ASCO [the American Society of Clinical Oncology annual meeting] for the HER2CLIMB trial. The safety data were reassuring; there were no new safety events or signals that were pick...
https://www.onclive.com/view/fda-grants-regular-approval-to-enfortumab-vedotin-expands-indication-for-locally-advanced-or-metastatic-urothelial-cancer
Jul 9th, 2021 - The FDA has granted a regular approval to enfortumab vedotin-ejfv (Padcev) and has expanded the agent's indication to include adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemothe...
https://www.onclive.com/view/zandelisib-zanubrutinib-yields-promising-responses-in-r-r-cll-and-b-cell-malignancies
Jun 11th, 2021 - A 60 mg dose of zandelisib (ME-401) administered on an intermittent schedule from cycle 1 plus 80 mg of zanubrutinib (Brukinsa) twice daily yielded promising response rates in patients with relapsed/refractory B-cell malignancies and chronic lymph...
https://www.onclive.com/view/pembrolizumab-plus-gemcitabine-hypofractionated-radiotherapy-demonstrates-promising-efficacy-in-muscle-invasive-bladder-cancer
Jun 7th, 2021 - Pembrolizumab (Keytruda) in combination with gemcitabine and concurrent hypofractionated radiotherapy (RT) appears to be a promising and efficacious, bladder-sparing regimen for patients with muscle-invasive bladder cancer (MIBC), according to fin...
https://www.onclive.com/view/neoadjuvant-pertuzumab-plus-trastuzumab-nab-paclitaxel-achieves-64-pcr-with-less-toxicity-in-her2-breast-cancer
Jun 6th, 2021 - The anthracycline-free regimen of pertuzumab (Perjeta) plus trastuzumab (Herceptin), and nab-paclitaxel (Abraxane) used as neoadjuvant therapy (NT) in patients with HER2-positive locally advanced breast cancer induced a pathologic complete respons...
